Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

VEGFR inhibitor

DRUG CLASS:

VEGFR inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	cediranib Resistant: A2 - Guideline cediranib Resistant : A2	cediranib Resistant: A2 - Guideline cediranib Resistant : A2